Soleno Therapeutics Inc.

Redwood City, CA Part of Neurocrine Biosciences, Inc.

UEI
DA8ADMFJRDU9
CAGE
72XA4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
Corporate family
SAM.gov registration date
Physical address
100 Marine Pkwy Suite 400, Redwood City, CA 94065, USA
Website
soleno.life
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Soleno Therapeutics Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Point of care breath test to screen for sickle cell disease in developing nations Grant · R44HL126469 National Heart Lung and Blood Institute -$3,171,846
Point-of-care end-tidal carbon monoxide measurement to screen for sickle cell disease Grant · R43HL126469 National Institutes of Health $219,917

About Soleno Therapeutics Inc.

Written by GovTribe AI ·

Soleno Therapeutics Inc. is a for-profit corporate entity based in Redwood City, California, specializing in pharmaceutical and medical product manufacturing. Registered in SAM.gov since January 2014 with a registration valid through June 2026, the company appears to focus on developing and supplying pharmaceutical and hematology-related products to federal agencies. While specific details about the company's core business are not provided in the award data, its federal contract history suggests a strong orientation toward medical product development and distribution.

The company has been awarded three significant federal contract indefinite delivery vehicles (IDVs) across multiple federal agencies. Two contracts are with the Veterans Integrated Service Network 12 (VISN 12) under the Federal Supply Schedule, with one being a $225,000 contract for drugs, pharmaceuticals, and hematology-related products valid through July 31, 2030, and another interim agreement valued at $25,000 through October 31, 2025. A third contract is a Blanket Purchase Agreement (BPA) with the National Acquisition Center, valued at $2,500,000 and running through May 19, 2026. These contracts are primarily situated under the Pharmaceuticals and Drugs (FSS-61-IB) parent GSA Schedule, focusing on procuring medical and pharmaceutical products for veterans' healthcare services. None of the contracts utilize set-asides, indicating Soleno Therapeutics competes on an open market basis across these federal procurement vehicles.

Contract vehicles

Soleno Therapeutics Inc. holds a place on 1 federal contract vehicle. Active vehicles first.

Quick answers

What is Soleno Therapeutics Inc.'s UEI?

Soleno Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is DA8ADMFJRDU9.

What is Soleno Therapeutics Inc.'s CAGE code?

Soleno Therapeutics Inc.'s CAGE code is 72XA4.

What is Soleno Therapeutics Inc.'s primary NAICS code?

Soleno Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Soleno Therapeutics Inc. located?

Soleno Therapeutics Inc.'s physical address in SAM.gov is 100 Marine Pkwy Suite 400, Redwood City, CA 94065, USA.

Is Soleno Therapeutics Inc. registered in SAM.gov?

Yes. Soleno Therapeutics Inc.'s SAM.gov registration is active through September 10, 2027.

Who is Soleno Therapeutics Inc.'s parent company?

Soleno Therapeutics Inc. is part of Neurocrine Biosciences, Inc.

Which contract vehicles does Soleno Therapeutics Inc. hold?

Soleno Therapeutics Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

What is Soleno Therapeutics Inc.'s most recent federal award?

Soleno Therapeutics Inc.'s most recent federal grant award is Point of care breath test to screen for sickle cell disease in developing nations (R44HL126469), from National Heart Lung and Blood Institute, on August 21, 2017.

On GovTribe

See Soleno Therapeutics Inc.'s full federal record

  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login